Researchers report that previous concern about a possible risk of thrombocytopenia in asthma patients treated with omalizumab is unfounded. Their conclusion is drawn from a large study of patients with moderate to severe allergic asthma, which showed that the frequency of clinically significant decreases in platelet counts was not increased with omalizumab compared with placebo.
Dr. Elliot Israel, with the Brigham and Women’s Hospital in Boston, Massachusetts, United States, presented the findings here March 9th at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology. Their study was prompted by a previous interim analysis of two pre-clinical safety trials, which found that omalizumab decreased platelet counts in a dose-dependent manner in juvenile (6 to 12-month old) cynomolgus monkeys.
However, there was no evidence of omalizumab-related decreases in platelet counts in the phase II and III clinical trials. In Dr. Israel’s study, 1,899 patients 6 to 76 year old were randomised in a 2:1 ratio to receive omalizumab at 0.008 mg/kg/ IgE (IU/mL) every 2 weeks or at 0.016 mg/kg every 4 weeks plus conventional asthma therapy, compared with conventional therapy alone.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!